All In Biotech

Free tool

FAERS Monitor: Lumakras

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 214665 or its brand name (Lumakras, Sotorasib). Reports on generic versions are filed under their own applications.

Reports

3,470

Serious

2,851

82% of reports

Hospitalization

705

Death reported

824

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • non-small cell lung cancer520
  • death415
  • disease progression348
  • diarrhoea334
  • off label use268
  • fatigue119
  • nausea119
  • hepatotoxicity103
  • hepatic function abnormal101
  • non-small cell lung cancer metastatic98
  • lung neoplasm malignant85
  • alanine aminotransferase increased81
  • aspartate aminotransferase increased80
  • decreased appetite77
  • drug ineffective75

Reports by year received

View as table
YearReports
2021198
2022714
20231,226
2024545
2025381
2026406

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,689 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
non-small cell lung cancer metastaticSignal98761.2618.665,438
non-small cell lung cancerSignal520737.9678.0340,596
hepatotoxicitySignal10328.223.32,662
disease progressionSignal34817.916.25,543
hepatic function abnormalSignal10116.413.61,449
lung neoplasm malignantSignal8512.610.2893
aspartate aminotransferase increasedSignal809.17.4573
alanine aminotransferase increasedSignal818.06.5490
diarrhoeaSignal3343.12.8499
deathSignal4152.92.7544
decreased appetiteSignal772.01.638
off label use2681.91.7109
fatigue1190.90.81
nausea1190.90.81
drug ineffective750.30.399

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.